Download - CML-CASE BASED DISCUSSION
![Page 1: CML-CASE BASED DISCUSSION](https://reader035.vdocuments.net/reader035/viewer/2022081508/556bcbbbd8b42a15608b4eae/html5/thumbnails/1.jpg)
Case based discussion
Pankaj MalhotraPGIMER, Chandigarh, India
![Page 2: CML-CASE BASED DISCUSSION](https://reader035.vdocuments.net/reader035/viewer/2022081508/556bcbbbd8b42a15608b4eae/html5/thumbnails/2.jpg)
Case History
• A 43-year old gentleman presented with weakness and fatigability x 3 months
• Hb 13.4 gm/dl, WBC 220,000 cells/mm3, Plat 679000 cells/mm3
• Spleen 10 cm• BM: Hypercellular, 8% blasts, Ph 20/20
positive, Q RT PCR for BCR ABL mRNA 80%• Sokal High-risk
![Page 3: CML-CASE BASED DISCUSSION](https://reader035.vdocuments.net/reader035/viewer/2022081508/556bcbbbd8b42a15608b4eae/html5/thumbnails/3.jpg)
Case History
• A 43-year old gentleman presented with weakness and fatigability x 3 months
• Hb 13.4 gm/dl, WBC 220,000 cells/mm3, Plat 679000 cells/mm3
• Spleen 10 cm• BM: Hypercellular, 8% blasts, Ph 20/20 positive,
Q RT PCR for BCR ABL mRNA 80%• Sokal High-risk• Availability of Imatinib/Dasatinib/Nilotinib
![Page 4: CML-CASE BASED DISCUSSION](https://reader035.vdocuments.net/reader035/viewer/2022081508/556bcbbbd8b42a15608b4eae/html5/thumbnails/4.jpg)
Choice of first line therapy Feb 2013
1. Imatinib 400 mg OD2. Imatinib 800 mg OD3. Dasatinib 100 mg OD4. Nilotinib 300 mg BD5. Nilotinib 400 mg BD6. Bosutinib 500 mg OD
Would Sokal high-risk score have impact on the choice of first line therapy?
![Page 5: CML-CASE BASED DISCUSSION](https://reader035.vdocuments.net/reader035/viewer/2022081508/556bcbbbd8b42a15608b4eae/html5/thumbnails/5.jpg)
Choice of first line therapy Feb 2013
1. Imatinib 400 mg OD2. Imatinib 800 mg OD3. Dasatinib 100 mg OD4. Nilotinib 300 mg BD5. Nilotinib 400 mg BD6. Bosutinib 500 mg OD
Does enough finances/insurance coverage impact on choice of first line therapy
![Page 6: CML-CASE BASED DISCUSSION](https://reader035.vdocuments.net/reader035/viewer/2022081508/556bcbbbd8b42a15608b4eae/html5/thumbnails/6.jpg)
Case History
• A 43-year old gentleman presented with weakness and fatigability x 3 months
• Hb 13.4 gm/dl, WBC 220,000 cells/mm3, Plat 679000 cells/mm3
• Spleen 10 cm• BM: Hypercellular, 8% blasts, Ph 20/20 positive,
Q RT PCR for BCR ABL mRNA 80%• Sokal High-risk• Active coronary artery disease and AF
![Page 7: CML-CASE BASED DISCUSSION](https://reader035.vdocuments.net/reader035/viewer/2022081508/556bcbbbd8b42a15608b4eae/html5/thumbnails/7.jpg)
Choice of first line therapy Feb 2013
1. Imatinib 400 mg OD2. Imatinib 800 mg OD3. Dasatinib 100 mg OD4. Nilotinib 300 mg BD5. Nilotinib 400 mg BD6. Bosutinib 500 mg OD
Would active coronary artery disease & AF impacts your decision making?
![Page 8: CML-CASE BASED DISCUSSION](https://reader035.vdocuments.net/reader035/viewer/2022081508/556bcbbbd8b42a15608b4eae/html5/thumbnails/8.jpg)
Case History
• A 43-year old gentleman presented with weakness and fatigability x 3 months
• Hb 13.4 gm/dl, WBC 220,000 cells/mm3, Plat 679000 cells/mm3
• Spleen 10 cm• BM: Hypercellular, 8% blasts, Ph 20/20 positive,
Q RT PCR for BCR ABL mRNA 80%• Sokal High-risk• Past history of pulmonary tuberculosis
![Page 9: CML-CASE BASED DISCUSSION](https://reader035.vdocuments.net/reader035/viewer/2022081508/556bcbbbd8b42a15608b4eae/html5/thumbnails/9.jpg)
Choice of first line therapy Feb 2013
1. Imatinib 400 mg OD2. Imatinib 800 mg OD3. Dasatinib 100 mg OD4. Nilotinib 300 mg BD5. Nilotinib 400 mg BD6. Bosutinib 500 mg OD
Would a past history of lung infection impacts your decision making?
![Page 10: CML-CASE BASED DISCUSSION](https://reader035.vdocuments.net/reader035/viewer/2022081508/556bcbbbd8b42a15608b4eae/html5/thumbnails/10.jpg)
Choice of first line therapy depends upon
1. Available finances/Full insurance2. Side effect profile of the drugs3. Co-morbid conditions of the patient4. Phase of the disease(Acc or BC)5. Sokal score (?)
![Page 11: CML-CASE BASED DISCUSSION](https://reader035.vdocuments.net/reader035/viewer/2022081508/556bcbbbd8b42a15608b4eae/html5/thumbnails/11.jpg)
![Page 12: CML-CASE BASED DISCUSSION](https://reader035.vdocuments.net/reader035/viewer/2022081508/556bcbbbd8b42a15608b4eae/html5/thumbnails/12.jpg)
Choice of first line therapy depends upon
1. Available finances/Full insurance2. Side effect profile of the drugs3. Co-morbid conditions of the patient4. Phase of the disease(Acc or BC)5. Sokal score (?)6. Physician preference/Patient preference (?)
![Page 13: CML-CASE BASED DISCUSSION](https://reader035.vdocuments.net/reader035/viewer/2022081508/556bcbbbd8b42a15608b4eae/html5/thumbnails/13.jpg)
Comparison of TKI
Favour Imatinib• Cheaper• Long-term experience• Known side effect profile• CCyR 70% at 1 year
• Less effective• More than 100 mutations
Favour 2nd G TKI• More effective • CCyR 80-85%• Fewer mutations (<10)
• Costly• Post marketing surveillance
suggest some unusual side effect
• Fewer options if disease progress
![Page 14: CML-CASE BASED DISCUSSION](https://reader035.vdocuments.net/reader035/viewer/2022081508/556bcbbbd8b42a15608b4eae/html5/thumbnails/14.jpg)
![Page 15: CML-CASE BASED DISCUSSION](https://reader035.vdocuments.net/reader035/viewer/2022081508/556bcbbbd8b42a15608b4eae/html5/thumbnails/15.jpg)
The patient was started on Imatinib 400 mg/day
![Page 16: CML-CASE BASED DISCUSSION](https://reader035.vdocuments.net/reader035/viewer/2022081508/556bcbbbd8b42a15608b4eae/html5/thumbnails/16.jpg)
Progress
• Achieved CHR by 2 months• RQ PCR for BCR-ABL at 3 months 22% IS
What are the long-term chances of PFS of this gentleman? ( RQ PCR >10% at 3 months)?
1. High2. Low
![Page 17: CML-CASE BASED DISCUSSION](https://reader035.vdocuments.net/reader035/viewer/2022081508/556bcbbbd8b42a15608b4eae/html5/thumbnails/17.jpg)
Progress
• Achieved CHR by 2 months• RQ PCR for BCR-ABL at 3 months 12% IS
What are the long-term chances of PFS of this gentleman? ( RQ PCR >10% at 3 months)?
1. High2. Low
![Page 18: CML-CASE BASED DISCUSSION](https://reader035.vdocuments.net/reader035/viewer/2022081508/556bcbbbd8b42a15608b4eae/html5/thumbnails/18.jpg)
![Page 19: CML-CASE BASED DISCUSSION](https://reader035.vdocuments.net/reader035/viewer/2022081508/556bcbbbd8b42a15608b4eae/html5/thumbnails/19.jpg)
![Page 20: CML-CASE BASED DISCUSSION](https://reader035.vdocuments.net/reader035/viewer/2022081508/556bcbbbd8b42a15608b4eae/html5/thumbnails/20.jpg)
The patient was started on Dasatinib 100 mg/day
![Page 21: CML-CASE BASED DISCUSSION](https://reader035.vdocuments.net/reader035/viewer/2022081508/556bcbbbd8b42a15608b4eae/html5/thumbnails/21.jpg)
Progress
• Achieved CHR by 2 months• RQ PCR for BCR-ABL at 3 months 12% IS
What are the long-term chances of PFS of this gentleman? ( RQ PCR >10% at 3 months)?
1. High2. Low
![Page 22: CML-CASE BASED DISCUSSION](https://reader035.vdocuments.net/reader035/viewer/2022081508/556bcbbbd8b42a15608b4eae/html5/thumbnails/22.jpg)
![Page 23: CML-CASE BASED DISCUSSION](https://reader035.vdocuments.net/reader035/viewer/2022081508/556bcbbbd8b42a15608b4eae/html5/thumbnails/23.jpg)
![Page 24: CML-CASE BASED DISCUSSION](https://reader035.vdocuments.net/reader035/viewer/2022081508/556bcbbbd8b42a15608b4eae/html5/thumbnails/24.jpg)
![Page 25: CML-CASE BASED DISCUSSION](https://reader035.vdocuments.net/reader035/viewer/2022081508/556bcbbbd8b42a15608b4eae/html5/thumbnails/25.jpg)
Thus with 2nd G TKI, you expect more rapid response, may be CCyR at 3 months/BCR ABL <2% at 3months
![Page 26: CML-CASE BASED DISCUSSION](https://reader035.vdocuments.net/reader035/viewer/2022081508/556bcbbbd8b42a15608b4eae/html5/thumbnails/26.jpg)
![Page 27: CML-CASE BASED DISCUSSION](https://reader035.vdocuments.net/reader035/viewer/2022081508/556bcbbbd8b42a15608b4eae/html5/thumbnails/27.jpg)
![Page 28: CML-CASE BASED DISCUSSION](https://reader035.vdocuments.net/reader035/viewer/2022081508/556bcbbbd8b42a15608b4eae/html5/thumbnails/28.jpg)
Assessment at 6 -months
• Glivec 400 mg/day continued• Hb 10.0 gm/dl MCV 102 WBC 3500 cells/mm3
Plat 100,000 cells/mm3• BM: Mild hypocellular• Cytogenetics 2/20 = MCyR• Q PCR 1% IS
What is your assessment and would you consider change in your strategy?
![Page 29: CML-CASE BASED DISCUSSION](https://reader035.vdocuments.net/reader035/viewer/2022081508/556bcbbbd8b42a15608b4eae/html5/thumbnails/29.jpg)
![Page 30: CML-CASE BASED DISCUSSION](https://reader035.vdocuments.net/reader035/viewer/2022081508/556bcbbbd8b42a15608b4eae/html5/thumbnails/30.jpg)
![Page 31: CML-CASE BASED DISCUSSION](https://reader035.vdocuments.net/reader035/viewer/2022081508/556bcbbbd8b42a15608b4eae/html5/thumbnails/31.jpg)
Current role of Allo HSCT
![Page 32: CML-CASE BASED DISCUSSION](https://reader035.vdocuments.net/reader035/viewer/2022081508/556bcbbbd8b42a15608b4eae/html5/thumbnails/32.jpg)
![Page 33: CML-CASE BASED DISCUSSION](https://reader035.vdocuments.net/reader035/viewer/2022081508/556bcbbbd8b42a15608b4eae/html5/thumbnails/33.jpg)
Conclusions
• Rapid advancement taking place in the field of CML
• Availability of many drugs have made life easy as well as difficult both for the physician as well as the patient
• Need to continue update our knowledge on CML on the basis of continuously emerging data